7 results about "Levocarnitine" patented technology

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The invention discloses a levocarnitine refining method which comprises the following steps: mixing and heating a levocarnitine crude product and a recrystallization solvent until the levocarnitine crude product and the recrystallization solvent are completely dissolved, then cooling and crystallizing, and carrying out suction filtration, washing and drying to obtain high-purity levocarnitine, wherein the recrystallization solvent comprises a first solvent and a second solvent; the first solvent is at least one of tetrahydrofuran, acetone, acetonitrile, n-butyl alcohol, ethyl acetate and N, N-dimethylformamide; the second solvent is at least one of water and ethanol; the mass ratio of the first solvent to the second solvent is 1: (0.2-8). According to the method disclosed by the invention, 4-(trimethyl ammonium) butyl-2-olefine acid inner salt and 4-(trimethyl amino)-2-butenamide impurities with similar structures in the levocarnitine crude product can be effectively removed, the purity of the product reaches 99.5% or above, the product meets the pharmacopoeia standard, and the quality of the product has obvious competitiveness.

The invention provides a preparation and purification method of (S)-3-chloro-2-hydroxypropyl trimethyl ammonium chloride, which comprises the following steps: dissolving trimethyl hydrochloride in methanol to obtain a solution, adding S-epichlorohydrin into the solution for reaction, partially or completely removing a reaction solvent after the reaction is finished, and then adding dichloromethane for pulping to remove impurities. According to the technical scheme, high-temperature distillation treatment is not needed, byproducts are few, especially biquaternary ammonium salt impurities grow slowly, hydrolysis impurities and basic toxic impurities such as S-epichlorohydrin can be effectively removed, and medication safety and effectiveness of the levocarnitine product are guaranteed.

This invention belongs to the field of pharmaceutical formulations, specifically relating to a levocarnitine oral gel and its preparation method. This invention discloses a stable levocarnitine oral gel composition comprising levocarnitine, a gel matrix, an alkali metal salt, and sodium polyacrylate. The stable levocarnitine oral gel disclosed in this invention is easy to swallow, has good medication adherence, does not undergo dehydration and shrinkage during the observation period, has stable product quality, good safety, and is convenient to carry and use; the process is simpler, with high production efficiency and lower risk, making it suitable for large-scale industrial production.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a pharmaceutical composition in the treatment of moderate fatty liver. This invention provides a combination of levocarnitine and trimetazidine, which, through the synergistic effect of levocarnitine and trimetazidine, treats moderate non-alcoholic fatty liver from the perspective of fat and glucose metabolism, thereby achieving its application in the treatment of moderate fatty liver.

The application discloses a method for determining potential genotoxic impurities in levocarnitine by GC-MS, comprising the following steps: preparing a test sample solution: taking 0.2-3g of levocarnitine, accurately weighing, placing in a centrifugal tube, adding 1-2ml of water, shaking to dissolve the sample, adding 5ml of acetone, first shaking to extract, then sealing and centrifuging, and taking the supernatant; preparing a control sample solution; respectively performing GC-MS detection on the control sample solution and the test sample solution, and determining the content of 2,3-dichloro-1-propanol and 1,3-dichloro-2-propanol in the levocarnitine by an external standard method. The application adopts GC-MS to determine the potential genotoxic impurities 2,3-dichloro-1-propanol and 1,3-dichloro-2-propanol in levocarnitine, and has high separation efficiency, fast analysis speed and high detection sensitivity, and can effectively control the quality of the levocarnitine.

This invention belongs to the pharmaceutical field, specifically relating to a compound pharmaceutical preparation for treating chronic uric acid nephropathy and its application. This invention provides a compound pharmaceutical preparation for treating chronic uric acid nephropathy, which is a tablet composed of levocarnitine and trimetazidine in a certain proportion. The levocarnitine and trimetazidine compound preparation can significantly improve renal function in patients with chronic uric acid nephropathy and protect against kidney damage.